CN1085206C - 可以增强ampa受体活性的苯并呋咱化合物 - Google Patents

可以增强ampa受体活性的苯并呋咱化合物 Download PDF

Info

Publication number
CN1085206C
CN1085206C CN98802541A CN98802541A CN1085206C CN 1085206 C CN1085206 C CN 1085206C CN 98802541 A CN98802541 A CN 98802541A CN 98802541 A CN98802541 A CN 98802541A CN 1085206 C CN1085206 C CN 1085206C
Authority
CN
China
Prior art keywords
compound
base carbonyl
crr
benzo furazan
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN98802541A
Other languages
English (en)
Chinese (zh)
Other versions
CN1247534A (zh
Inventor
加里·A·罗杰斯
克里斯托弗·M·马尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of CN1247534A publication Critical patent/CN1247534A/zh
Application granted granted Critical
Publication of CN1085206C publication Critical patent/CN1085206C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Hydrogenated Pyridines (AREA)
  • Furan Compounds (AREA)
  • Luminescent Compositions (AREA)
CN98802541A 1997-02-13 1998-02-13 可以增强ampa受体活性的苯并呋咱化合物 Expired - Fee Related CN1085206C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/800,108 1997-02-13
US08/800,108 US6110935A (en) 1997-02-13 1997-02-13 Benzofurazan compounds for enhancing glutamatergic synaptic responses

Publications (2)

Publication Number Publication Date
CN1247534A CN1247534A (zh) 2000-03-15
CN1085206C true CN1085206C (zh) 2002-05-22

Family

ID=25177504

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98802541A Expired - Fee Related CN1085206C (zh) 1997-02-13 1998-02-13 可以增强ampa受体活性的苯并呋咱化合物

Country Status (24)

Country Link
US (3) US6110935A (cg-RX-API-DMAC10.html)
EP (2) EP0960105B1 (cg-RX-API-DMAC10.html)
JP (1) JP4446023B2 (cg-RX-API-DMAC10.html)
KR (1) KR100544295B1 (cg-RX-API-DMAC10.html)
CN (1) CN1085206C (cg-RX-API-DMAC10.html)
AT (2) ATE266649T1 (cg-RX-API-DMAC10.html)
AU (1) AU737802C (cg-RX-API-DMAC10.html)
BR (1) BR9807333B1 (cg-RX-API-DMAC10.html)
CA (1) CA2279319C (cg-RX-API-DMAC10.html)
CZ (1) CZ299765B6 (cg-RX-API-DMAC10.html)
DE (2) DE69823803T2 (cg-RX-API-DMAC10.html)
DK (2) DK1428534T3 (cg-RX-API-DMAC10.html)
ES (2) ES2264078T3 (cg-RX-API-DMAC10.html)
GB (1) GB2325225B (cg-RX-API-DMAC10.html)
HU (1) HUP0002303A3 (cg-RX-API-DMAC10.html)
ID (1) ID22342A (cg-RX-API-DMAC10.html)
IL (1) IL131200A (cg-RX-API-DMAC10.html)
NO (1) NO318935B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ336980A (cg-RX-API-DMAC10.html)
PL (1) PL199135B1 (cg-RX-API-DMAC10.html)
PT (2) PT1428534E (cg-RX-API-DMAC10.html)
RU (1) RU2189984C2 (cg-RX-API-DMAC10.html)
TR (1) TR199901941T2 (cg-RX-API-DMAC10.html)
WO (1) WO1998035950A1 (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN188837B (cg-RX-API-DMAC10.html) 1998-05-22 2002-11-09 Torrent Pharmaceuticals Ltd
AU2002366756A1 (en) * 2001-12-20 2003-07-09 Alangudi Sankaranarayanan Use of benzofuroxan derivatives as antiplatelet agents
PL378366A1 (pl) * 2003-01-13 2006-04-03 Cortex Pharmaceuticals, Inc. Sposób leczenia osłabienia funkcji poznawczych spowodowanego deprywacją snu i stresem
PT1636215E (pt) * 2003-05-23 2008-04-29 Basilea Pharmaceutica Ag Furazanobenzimidazoles
ATE556710T1 (de) * 2004-01-26 2012-05-15 Cortex Pharma Inc Verbesserung der durch ampakine induzierten erleichterung von synaptischen reaktionen durch cholinesterase-inhibitoren
BRPI0716375A2 (pt) * 2006-08-31 2013-10-15 Univ Alberta Método para reduzir ou inibir depressão respiratória em um sujeito; método para induzir analgesia, anestesia ou sedação em um sujeito, reduzindo ou inibindo simultaneamente depressão respiratória no sujeito; e composição farmacêutica para induzir analgesia, anestesia ou sedação em um sujeito...
CA2674321A1 (en) * 2007-01-03 2008-07-17 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
ZA200904826B (en) * 2007-01-03 2010-09-29 Cortex Pharma Inc 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
JP5694765B2 (ja) * 2007-05-17 2015-04-01 コーテックス ファーマシューティカルズ, インコーポレイテッド グルタミン酸作動性シナプス反応を増強するための二置換アミド
US8168632B2 (en) 2007-08-10 2012-05-01 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for the treatment of respiratory disorders
ES2560095T3 (es) 2007-08-10 2016-02-17 Cortex Pharmaceuticals, Inc. Amidas bicíclicas para mejorar las respuestas sinápticas glutamatérgicas
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
US20110218190A1 (en) * 2008-11-10 2011-09-08 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
WO2010087980A2 (en) * 2009-02-02 2010-08-05 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for the treatment of respiratory depression
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
AU2012225784B2 (en) 2011-03-04 2016-03-17 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
CN102633731B (zh) * 2012-03-13 2014-04-30 四川大学华西医院 6-喹喔啉甲酸酰胺化合物、制备方法和应用
KR101421032B1 (ko) * 2012-12-28 2014-07-22 주식회사 레고켐 바이오사이언스 (2-메틸-1-(3-메틸벤질)-1H-벤조[d]이미다졸-5일)(피페리딘-5-일)메탄온의 제조방법
EP3311842A1 (en) 2013-06-13 2018-04-25 VeroScience LLC Compositions and methods for treating metabolic disorders
EP3436021B1 (en) 2016-03-29 2026-07-29 RespireRx Pharmaceuticals, Inc. Compositions comprising low impact ampakines for treating attention deficit disorders
CN107286114B (zh) 2016-04-13 2020-08-18 中国人民解放军军事医学科学院毒物药物研究所 Ampa受体增效剂的脑靶向前药及其医药用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002475A1 (en) * 1992-07-24 1994-02-03 The Regents Of The University Of California Drugs that enhance synaptic responses mediated by ampa receptors
EP0709384A1 (de) * 1994-10-31 1996-05-01 MERCK PATENT GmbH Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3981864A (en) * 1973-09-08 1976-09-21 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
FR2499991A1 (fr) * 1981-02-19 1982-08-20 Sandoz Sa Nouveaux 2,1,3-benzothiadiazoles et 2,1,3-benzoxadiazoles, leur preparation et leur application comme medicaments
US4420485A (en) * 1982-09-29 1983-12-13 Hoechst-Roussel Pharmaceuticals Inc. 1'-[3-(1,2-Benzisoxazol-3-yl) proply]spiro[benzofuran-2(3H),3' or 4'-piperidines or 3'-pyrrolidines]
SU1657189A1 (ru) * 1988-05-23 1991-06-23 Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср Способ коррекции апато-абулических состо ний при шизофрении
SU1587050A1 (ru) * 1988-12-23 1990-08-23 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского Производные (7-бромбензо-2,1,3-тиадиазол-4-сульфонил)амина в качестве промежуточных продуктов в синтезе 2-[(7-бромбензо-2,1,3-тиадиазол-4-сульфонил)амино]-5-бром-N-(4-хлорфенил)бензамида, обладающего антигельминтной активностью
US5112824A (en) * 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
US5032604A (en) * 1989-12-08 1991-07-16 Merck & Co., Inc. Class III antiarrhythmic agents
IL96507A0 (en) * 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
US5985871A (en) 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002475A1 (en) * 1992-07-24 1994-02-03 The Regents Of The University Of California Drugs that enhance synaptic responses mediated by ampa receptors
EP0709384A1 (de) * 1994-10-31 1996-05-01 MERCK PATENT GmbH Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren

Also Published As

Publication number Publication date
NO993768L (no) 1999-09-23
NZ336980A (en) 2000-08-25
NO993768D0 (no) 1999-08-04
GB2325225B (en) 1999-03-03
DE69834590D1 (de) 2006-06-22
BR9807333B1 (pt) 2011-10-18
PT960105E (pt) 2004-09-30
JP2001512459A (ja) 2001-08-21
PL335058A1 (en) 2000-03-27
CZ279599A3 (cs) 2000-01-12
KR20000071082A (ko) 2000-11-25
EP1428534B1 (en) 2006-05-17
CA2279319A1 (en) 1998-08-20
DK0960105T3 (da) 2004-08-30
JP4446023B2 (ja) 2010-04-07
NO318935B1 (no) 2005-05-30
HUP0002303A2 (hu) 2001-04-28
DE69834590T2 (de) 2007-04-26
HUP0002303A3 (en) 2002-09-30
EP0960105A1 (en) 1999-12-01
AU6159998A (en) 1998-09-08
IL131200A0 (en) 2001-01-28
PT1428534E (pt) 2006-07-31
GB2325225A (en) 1998-11-18
US6730677B2 (en) 2004-05-04
TR199901941T2 (xx) 1999-12-21
US6313115B1 (en) 2001-11-06
DK1428534T3 (da) 2006-06-12
RU2189984C2 (ru) 2002-09-27
CA2279319C (en) 2008-08-05
ATE266649T1 (de) 2004-05-15
ES2221152T3 (es) 2004-12-16
US20020055508A1 (en) 2002-05-09
US6110935A (en) 2000-08-29
ATE326221T1 (de) 2006-06-15
CN1247534A (zh) 2000-03-15
PL199135B1 (pl) 2008-08-29
EP0960105B1 (en) 2004-05-12
AU737802C (en) 2005-05-12
ID22342A (id) 1999-09-30
CZ299765B6 (cs) 2008-11-19
DE69823803T2 (de) 2005-04-14
IL131200A (en) 2005-06-19
GB9809221D0 (cg-RX-API-DMAC10.html) 1998-07-01
DE69823803D1 (de) 2004-06-17
WO1998035950A1 (en) 1998-08-20
EP1428534A1 (en) 2004-06-16
GB2325225A8 (en) 1999-02-17
ES2264078T3 (es) 2006-12-16
AU737802B2 (en) 2001-08-30
KR100544295B1 (ko) 2006-01-23
BR9807333A (pt) 2000-04-18

Similar Documents

Publication Publication Date Title
CN1247534A (zh) 可以增强ampa受体活性的苯并呋喃化合物
CA2450801C (en) Drugs that enhance synaptic responses mediated by ampa receptors
CN101742911A (zh) 用于增强谷氨酸能突触反应的二取代的酰胺
CN1186020C (zh) 用于提高突触应答的酰基苯并噁嗪
JP4620349B2 (ja) グルタメートシナプシス応答向上のためのカルボニルベンゾキサジン化合物
US20020099050A1 (en) Drugs that enhance synaptic responses mediated by AMPA receptors
AU725127B2 (en) Drugs that enhance synaptic responses mediated by AMPA receptors
MXPA99007361A (en) Benzofurazan compounds which enhance ampa receptor activity
US20020055498A1 (en) Benzofurazan compounds for enhancing glutamatergic synaptic responses
JP2012516845A (ja) グルタミン酸作動性シナプス反応を増強するための二環式アミド誘導体
HK1073106A (en) Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
HK1163693A (en) Bicyclic amide derivatives for enhancing glutamatergic synaptic responses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20020522

Termination date: 20130213